CHF Solutions Inc (CHFS)

ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure

Treatment with Aquadex therapy showed significant weight decrease, clinical symptom improvement and decreased readmissions among heart failure patients.

Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology

Gentle Ultrafiltration with Aquadex SmartFlow® Expands Options for Pediatric Patients

Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update

Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021

CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis

The new name reflects the company’s commitment to pediatric, critical care, and chronic heart failure patients

CHF Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Two Texas Hospitals

CHF Solutions Announces First Patient Enrolled in the ULTRA-Peds Registry

Registry will Support Real-World Efficacy of Fluid Management in Children

The Portability of Aquadex SmartFlow® from CHF Solutions Could Mean More Critically-Ill Patients Have Access to Life-Saving Ultrafiltration Therapy

New Clinical Abstract Available Online During National Kidney Foundation Spring Clinical Meeting (NKF)

CHF Solutions, Inc. Announces Closing of $20.9 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

EDEN PRAIRIE, Minn., March 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the closing of its pre...

CHF Solutions, Inc. Announces Closing of $20.9 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

CHF Solutions, Inc. Announces Pricing of $18.1 Million Underwritten Public Offering of Common Stock

CHF Solutions, Inc. Announces Proposed Underwritten Public Offering of Common Stock

CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems

CHF Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Puerto Rico

CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients

CHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update

CHF Solutions, Inc. To Announce Fourth Quarter 2020 Financial Results on March 2, 2021

CHF Solutions Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability